Antimalarial workshop

Journal of Rheumatology

Volumn 24, Issue 7, 1997, Pages 1393-1395

  Beattie, Craig ^a   Beaudet, François ^a   Davis, Paul ^b   Dochery, Peter ^c   Easterbrook, Michael ^d   Fitzcharles, Mary Ann ^e   Gordon, Duncan A ^f   Koehler, Barry ^a   Ménard, Henri A ^g   Pope, Janet ^h   Smith, C Douglas ⁱ   Thorne, J Carter ^d   Turcotte, Pierre ^j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITÉ DE SHERBROOKE   (Canada)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j UNIVERSITÉ LAVAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE;

ANTIMALARIAL ACTIVITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; EYE TOXICITY; HUMAN; MONITORING; PRIORITY JOURNAL; RHEUMATIC DISEASE;

ANTIMALARIALS; HUMANS; RHEUMATIC DISEASES;

EID: 0007639571     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Emery P, Salmon M: Early rheumatoid arthritis: Time to aim for remission? Ann Rheum Dis 1995;54:944-7.
2. Smith MD, Ahern MJ: Disease-modifying antirheumatic drugs. Med J Australia 1992;157:797-801.
3. Paton TW: Rheumatoid arthritis. In: Gray J, ed. Therapeutic Choices. Ottawa: Canadian Pharmaceutical Association, 1995:375-80.
4. Kay EA: Prescribing of chloroquine and hydroxychloroquine by consultant rheumatologists in the UK. Br J Rheumatol 1987;26:375-8.
5. Prashker MJ, Meenan RF: The total costs of drug therapy for rheumatoid arthritis. Arthritis Rheum 1995;38:318-25.
6. Davis MJ, Dawes PT, Fowler PD, et al: Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991;30:451-4.
7. The HERA Study Group: A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study. Am J Med 1995;98:156-68.
8. Clark P, Casas E, Tugwell P, et al: Hydroxychloroquine compared with placebo in rheumatoid arthritis. Ann Intern Med 1993;119:1067-71.
9. Nishihara KK, Furst DE: Hydroxychloroquine and its use in rheumatoid arthritis. Communications Media for Education Inc., Princeton Junction, New Jersey. Today's Therapeutic Trends 1995;13:109-24.
10. Husain Z, Runge LA: Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine. D-penicillamine, and levamisole. J Rheumatol 1980;7:825-30.
11. Singleton PT, Cervantes AG: Chrysotherapy and concomitant use of antimalarial drug therapy in rheumatoid arthritis (abstr). Arthritis Rheum 1982;(suppl)25:S115.
12. Scott DL, Dawes PT, Tunn E, et al: Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis. Br J Rheumatol 1989;28:128-33.
13. O'Dell JR, Haire CE, Erikson N, et al: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.